The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

NCT02829502 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether a GLP-1 receptor agonist affects blood flow and oxygen levels in the brain of adults who have had an ischemic stroke.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 30 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2016-08 · est. completion 2023-11

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02829502 ↗

Description as written by the study sponsor.

This randomized controlled trial investigates the effect of a single dose of glucagon-like peptide-1 (GLP-1) receptor agonist in the subacute phase of stroke in humans. The primary endpoint is the mean flow velocity in the middle cerebral arteries measured by transcranial doppler and cortical oxygination measured by near infrared spectroscopy (NIRS). The secondary endpoints are changes in endothelial/inflammatory biomarkers in the blood, changes in the ankle-brachial index and changes in the reactive hyperaemia index measured by EndoPAT2000.

Treatments tested

Byetta also known as Exenatide, GLP-1 receptor analogue, GLP-1 receptor agonist Drug

Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
Normosaline also known as Isotonic saline Drug

Single dose of subcutaneous injection of 20 μL normosaline (placebo).

Main thing measured	Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination.
Sponsor	Christina Kruuse
Conditions studied	Ischemic Stroke
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02829502 ↗